Biohaven Ltd. will present an investor presentation detailing its ongoing and planned trials for various development programs, including troriluzole, taldefgrobep ...

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

In addition to TD Cowen, Biohaven Ltd. also received a Buy from William Blair’s Myles Minter in a report issued today. However, yesterday, RBC Capital maintained a Hold rating on Biohaven Ltd. (NYSE: ...

Morgan Stanley analyst Terence Flynn reiterated a Buy rating on Biohaven Ltd. ( BHVN – Research Report) today and set a price target of $63.00. The company’s shares opened today at $15.43.

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

The Spinocerebellar Ataxia pipeline is advancing fast as troriluzole nears FDA nod and rivals race with gene and stem cell therapies to seize market edge. Disease modification in spinocerebellar ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...